Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H16N4O.2C2H6O4S |
Molecular Weight | 532.588 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCS(O)(=O)=O.OCCS(O)(=O)=O.NC(=N)C1=CC=C(C=CC2=C(O)C=C(C=C2)C(N)=N)C=C1
InChI
InChIKey=XVTQTNAKZYLTNZ-UHFFFAOYSA-N
InChI=1S/C16H16N4O.2C2H6O4S/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21;2*3-1-2-7(4,5)6/h1-9,21H,(H3,17,18)(H3,19,20);2*3H,1-2H2,(H,4,5,6)
Molecular Formula | C16H16N4O |
Molecular Weight | 280.3244 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
Molecular Formula | C2H6O4S |
Molecular Weight | 126.132 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.springer.com/us/book/9780751404999Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/1933270
Sources: http://www.springer.com/us/book/9780751404999
Curator's Comment: description was created based on several sources, including, http://www.ncbi.nlm.nih.gov/pubmed/1933270
Hydroxystilbamidine is an organic antimonal derivative with antiprotazoal, antifungal and anticancer activity. It was used in the treatment of blastomicosis and leishmaniasis. Moreover, hydroxystilbamidine (FluoroGold) is used as a tracer for neurons.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/16555054
Curator's Comment: Hydroxystilbamidine enters CNs and thus is used as a retrograde tracer for neurons. All the experiments on CNS penetration were done using rats, although the same is applicable for human.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
32.6 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
43.4 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.4 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
20% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: DOXYLAMINE |
PYRIDOXINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
225 mg 1 times / day multiple, intravenous Dose: 225 mg, 1 times / day Route: intravenous Route: multiple Dose: 225 mg, 1 times / day Sources: |
unhealthy, 7 years n = 1 Health Status: unhealthy Condition: BLASTOMYCOSIS Age Group: 7 years Sex: F Population Size: 1 Sources: |
Other AEs: Hepatic failure... |
45.2 g 1 times / day multiple, intravenous Highest studied dose Dose: 45.2 g, 1 times / day Route: intravenous Route: multiple Dose: 45.2 g, 1 times / day Sources: |
unhealthy n = 1 Health Status: unhealthy Condition: BLASTOMYCOSIS Population Size: 1 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hepatic failure | grade 5|acute | 225 mg 1 times / day multiple, intravenous Dose: 225 mg, 1 times / day Route: intravenous Route: multiple Dose: 225 mg, 1 times / day Sources: |
unhealthy, 7 years n = 1 Health Status: unhealthy Condition: BLASTOMYCOSIS Age Group: 7 years Sex: F Population Size: 1 Sources: |
Sample Use Guides
A total dose of 8 mg is given in daily doses of 225 mg in 200 ml of 5 percent dextrose by slow infusion.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/13174872
Hairs infected with Microsporum audouini, M. canis, and Trichophyton schoenleini, respectively, as well as thick nail clippings infected with T. rubrum, were suspended for 72 hours at 30°C in 0.225 % aqueous solutions of hydroxystilbamidine. The minimum fungistatic concentration ranged from 60 ug/ml to 1000 ug/ml of Sabouraud's agar.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:58:54 GMT 2023
by
admin
on
Fri Dec 15 14:58:54 GMT 2023
|
Record UNII |
0163PVD2QZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C514
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C65871
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
DB01040
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
259242
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
100000086958
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
10779
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
533-22-2
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
m6153
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
CHEMBL1301
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
0163PVD2QZ
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
SUB02596MIG
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY | |||
|
208-557-3
Created by
admin on Fri Dec 15 14:58:54 GMT 2023 , Edited by admin on Fri Dec 15 14:58:54 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |